title: Extracorporeal bioartificial liver using the radial-flow bioreactor in treatment of fatal experimental hepatic encephalopathy.
abstract: An extracorporeal bioartificial liver (BAL) that could prevent death from hepatic encephalopathy in acute hepatic insufficiency was aimed to develop. A functional human hepatocellular carcinoma cell line (FLC-4) was cultured in a radial-flow bioreactor. The function of the BAL was tested in mini-pigs with acute hepatic failure induced by alpha-amanitin and lipopolysaccharide. When the BAL system was connected with cultured FLC-4 to three pigs with hepatic dysfunction, all demonstrated electroencephalographic improvement and survived. Relatively low plasma concentrations of S-100 beta protein, as a marker of astrocytic damage, from pigs with hepatic failure during BAL therapy were noted. BAL therapy can prevent irreversible brain damage from hepatic encephalopathy in experimental acute hepatic failure.
authors.affiliation: Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Kanai
authors.forename: Hideki
authors.initials: H
authors.lastname: Marushima
authors.forename: Naofumi
authors.initials: N
authors.lastname: Kimura
authors.forename: Takamasa
authors.initials: T
authors.lastname: Iwaki
authors.forename: Masaya
authors.initials: M
authors.lastname: Saito
authors.forename: Haruka
authors.initials: H
authors.lastname: Maehashi
authors.forename: Keiko
authors.initials: K
authors.lastname: Shimizu
authors.forename: Makiko
authors.initials: M
authors.lastname: Muto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Masaki
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ohkawa
authors.forename: Keitaro
authors.initials: K
authors.lastname: Yokoyama
authors.forename: Masaaki
authors.initials: M
authors.lastname: Nakayama
authors.forename: Tohru
authors.initials: T
authors.lastname: Harada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hano
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Hataba
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fukuda
authors.forename: Masahiko
authors.initials: M
authors.lastname: Nakamura
authors.forename: Naoto
authors.initials: N
authors.lastname: Totsuka
authors.forename: Shutaro
authors.initials: S
authors.lastname: Ishikawa
authors.forename: Yasuki
authors.initials: Y
authors.lastname: Unemura
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ishii
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Yanaga
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Matsuura
mesh_terms: D000546:Amanitins; D000818:Animals; D019149:Bioreactors; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D006501:Hepatic Encephalopathy / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D008070:Lipopolysaccharides; D019164:Liver, Artificial; D008297:Male; D009414:Nerve Growth Factors / Q000097:blood; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood; D013552:Swine; D013556:Swine, Miniature
chemical_list: D000546:Amanitins; D008070:Lipopolysaccharides; D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins